| Name | Title | Contact Details |
|---|---|---|
Ian Richardson |
Director, Engineering, Information Security Officer | Profile |
Sudipto Sur |
Chief Technology Officer | Profile |
AdvanDx is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MedLite ID is an easy-to-use, disposable medical device that enables clinicans to accurately and efficiently identify a single medication infusion line against similar infusion lines in any light setting. The ninth leading cause of medical-error deaths in the United States involves infusion line confusion, and nearly 65 percent of those cases are related to the medication infusion line. MedLite ID eliminates infusion confusion by providing indicators with built-in wireless light technology at the medication bag, connector, and to patient. Each MedLite ID device is unique to its individual medication infusion line and cuts the process of infusion line identification to mere seconds. This saves clinicians precious time while also drastically mitigating risk and reducing stress while ensuring better care and patient outcomes.
Based in California, Lumitron Technologies Inc. was established to develop and commercialize unique x‐ray systems that enable revolutionary new capabilities for ultrahigh‐fidelity imaging, ultra‐low dose radiography, hyper‐precision radiotherapy, as well as element-specific and isotope-specific material identification, assay and imaging.
Martab Physicians Hospital Supply Co. is a Mahwah, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Elucid is a Boston-based medical technology company using uniquely interpretable and validated AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. Advanced clinical insight from Elucid equips physicians with critical information designed to enable precision medicine. Elucid is the first FDA-Cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company has published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall and estimation of coding and non-coding RNA transcripts (“Virtual Transcriptomics”). This unique information informs improved treatment decisions by physicians leading to better patient outcomes, improved quality of care, and reduced healthcare costs. The Elucid software is available for commercial use in the U.S. and Europe